The Effect of Nitozumab in the Treatment of Head and Neck Squamous Cell Carcinoma

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 17, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

HNSCC

Interventions

DRUG

Nituozumab

Nituozumab injection 200mg, administered once a week on the first day, with a duration of at least 60 minutes for a total of 7 times

Trial Locations (1)

RECRUITING

Sichuan Cancer Hospital and Research Institute, Chengdu

All Listed Sponsors

lead

Sichuan Cancer Hospital and Research Institute

OTHER